ES2350053T3 - Derivados de ácido-30-amida glicirretínico y usos de los mismos. - Google Patents

Derivados de ácido-30-amida glicirretínico y usos de los mismos. Download PDF

Info

Publication number
ES2350053T3
ES2350053T3 ES06791264T ES06791264T ES2350053T3 ES 2350053 T3 ES2350053 T3 ES 2350053T3 ES 06791264 T ES06791264 T ES 06791264T ES 06791264 T ES06791264 T ES 06791264T ES 2350053 T3 ES2350053 T3 ES 2350053T3
Authority
ES
Spain
Prior art keywords
methyl
isoxazol
formula
compound
deoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES06791264T
Other languages
English (en)
Spanish (es)
Inventor
Weiren Xu
Lida Tang
Jianwu Wang
Jianping Yong
Yuli Wang
Shijun Zhang
Lijun Liu
Xiaowen Ren
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tianjin Institute of Pharmaceutical Research Co Ltd
Original Assignee
Tianjin Institute of Pharmaceutical Research Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tianjin Institute of Pharmaceutical Research Co Ltd filed Critical Tianjin Institute of Pharmaceutical Research Co Ltd
Application granted granted Critical
Publication of ES2350053T3 publication Critical patent/ES2350053T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES06791264T 2005-10-14 2006-10-16 Derivados de ácido-30-amida glicirretínico y usos de los mismos. Active ES2350053T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CNB2005100153718A CN100488979C (zh) 2005-10-14 2005-10-14 甘草次酸-30-酰胺类衍生物及其用途
CN200510015371 2005-10-14

Publications (1)

Publication Number Publication Date
ES2350053T3 true ES2350053T3 (es) 2011-01-17

Family

ID=37942322

Family Applications (1)

Application Number Title Priority Date Filing Date
ES06791264T Active ES2350053T3 (es) 2005-10-14 2006-10-16 Derivados de ácido-30-amida glicirretínico y usos de los mismos.

Country Status (9)

Country Link
US (1) US7790759B2 (enExample)
EP (1) EP1935892B1 (enExample)
JP (1) JP5286087B2 (enExample)
CN (1) CN100488979C (enExample)
AT (1) ATE477019T1 (enExample)
AU (1) AU2006301708B2 (enExample)
DE (1) DE602006016146D1 (enExample)
ES (1) ES2350053T3 (enExample)
WO (1) WO2007041969A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101229172B (zh) * 2007-12-28 2010-10-27 天津药物研究院 甘草次酸30-酰胺类衍生物的固体分散物、其制备方法和用途
WO2009090063A1 (en) * 2008-01-16 2009-07-23 Jado Technologies Gmbh Steroid sapogenin, androstane and triterpenoid sapogenin derivatives for the treatment and prevention of infectious diseases
KR101220182B1 (ko) * 2009-02-25 2013-01-11 에스케이바이오팜 주식회사 치환된 아졸 유도체 화합물, 이를 포함하는 약제학적 조성물 및 이를 이용한 파킨슨씨 병 치료방법
CN101899081B (zh) * 2009-05-31 2012-09-05 江苏正大天晴药业股份有限公司 甘草次酸酯类衍生物合成方法以及脱氧甘草次酸酯化合物
CN102653550A (zh) * 2011-03-01 2012-09-05 广西壮族自治区药用植物园 甘草次酸的制备及用途
CN102250187B (zh) * 2011-04-25 2013-03-27 北京中海康医药科技发展有限公司 一种甘草次酸衍生物及其制备方法
CN102241726B (zh) * 2011-05-27 2013-06-12 苏州大学 甘草次酸衍生物及其作为抗肿瘤药物的应用
CN102813661B (zh) * 2011-06-09 2014-04-09 天津药物研究院 一种甘草次酸衍生物的用途
TWI424839B (zh) 2011-10-27 2014-02-01 Univ Kaohsiung Medical 18β－甘草次酸衍生物及其用途
CN103102383A (zh) * 2011-11-14 2013-05-15 天津药物研究院 甘草次酸-30-酰胺类衍生物的晶型a及其制备方法
CN103102382A (zh) * 2011-11-14 2013-05-15 天津药物研究院 甘草次酸-30-酰胺类衍生物的晶型b及其制备方法
CN102579462B (zh) * 2012-01-18 2013-05-22 苏州大学 甘草次酸衍生物制备抗炎药物中的应用
CN102838651B (zh) * 2012-09-26 2014-05-28 天津药物研究院 一类齐墩果酸的衍生物及其制备方法和用途
JP6227665B2 (ja) * 2013-11-25 2017-11-08 株式会社アイ・エヌ・アイ グリチルレチン酸誘導体及びその利用
US9896476B1 (en) 2017-09-21 2018-02-20 King Saud University Glycyrrhetic acid derivatives
CN107619425A (zh) * 2017-09-21 2018-01-23 南京师范大学 一种尾接有机导向分子的芳基钌配合物及其合成方法和应用
CN110776549B (zh) * 2019-11-25 2021-06-11 烟台大学 含氮杂环甘草次酸衍生物及其制备方法和抗甲型流感病毒应用
CN111018938B (zh) * 2019-12-10 2021-05-25 中国人民解放军第二军医大学 一种五环三萜类甘草次酸衍生物及制备方法与应用
CN118561945A (zh) * 2024-05-22 2024-08-30 厦门稀土材料研究所 18β-甘草次酸酯类衍生物及其制备方法和用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1447162A (en) * 1974-03-12 1976-08-25 Landerlan Sa Lab Triterpene derivatives
GB1516271A (en) * 1976-03-15 1978-06-28 Biorex Laboratories Ltd Glycyrrhetinic acid derivatives
GB2140809A (en) * 1983-06-01 1984-12-05 Biorex Laboratories Ltd New derivatives of glycyrrhetinic acid
GB0105772D0 (en) 2001-03-08 2001-04-25 Sterix Ltd Use
DE10307388A1 (de) * 2003-02-21 2004-09-02 Cognis Deutschland Gmbh & Co. Kg Glyzyrrhetinsäureester
CN1812824A (zh) * 2003-06-30 2006-08-02 麦克公司 作为雄激素受体调节剂的17－乙酰氨基－4－氮杂甾体衍生物
CN1257182C (zh) 2004-04-06 2006-05-24 南开大学 甘草次酸的制备方法

Also Published As

Publication number Publication date
AU2006301708A1 (en) 2007-04-19
CN100488979C (zh) 2009-05-20
EP1935892A4 (en) 2009-04-01
EP1935892A1 (en) 2008-06-25
AU2006301708B2 (en) 2011-06-23
US20080214636A1 (en) 2008-09-04
ATE477019T1 (de) 2010-08-15
DE602006016146D1 (de) 2010-09-23
CN1948332A (zh) 2007-04-18
EP1935892B1 (en) 2010-08-11
JP5286087B2 (ja) 2013-09-11
JP2009511511A (ja) 2009-03-19
WO2007041969A1 (fr) 2007-04-19
US7790759B2 (en) 2010-09-07

Similar Documents

Publication Publication Date Title
ES2350053T3 (es) Derivados de ácido-30-amida glicirretínico y usos de los mismos.
ES2358426T3 (es) Compuestos para la inflamación y usos inmunorrelacionados.
ES2266227T3 (es) Nuevos compuestos de (tio)urea y composiciones farmaceuticas que los contienen.
ES2217956B1 (es) Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo.
DK149886B (da) Analogifremgangsmaade til fremstilling af 5-methylisoxazol-4-carboxylsyre-(4-trifluormethyl)-anilid
TW200806641A (en) Substituted aromatic compounds for inflammation and immune-related uses
JPS6116275B2 (enExample)
US10383866B2 (en) Alkyl dihydroquinoline sulfonamide compounds
CA3008485C (en) Alkynyl dihydroquinoline sulfonamide compounds
ES2215919T3 (es) Derivados de cumarina con actividad inhibidora de comt.
BR112020014584A2 (pt) inibição do canal iônico do receptor de potencial transitório a1
JPS63295537A (ja) 新規化合物、医療組成物、及び炎症及び痛みの治療方法
TWI815820B (zh) ２－（５－（４－（２－嗎啉乙氧基）苯基）吡啶－２－基）－ｎ－芐乙醯胺之固態形式
US11236041B2 (en) Type-G crystal form of fenolamine, preparation method, composition and use thereof
EP3653601B1 (en) Fenlean (flz) crystal b form, preparation method, and composition and use thereof
CN103739576B (zh) 一种抗病毒穿心莲内酯衍生物及其制备方法和应用
US3141024A (en) S-trimethoxy benzoyl amino
JPH02237928A (ja) 置換ベンズアミドより成る胃の自動運動性増進用薬剤
ES2347681T3 (es) Agentes para tratar el herpes genital despues de su aparicion.
JPS5835186A (ja) ジカルボキシアミノチアゾール誘導体およびそれを含有する免疫調節組成物
CN115073442B (zh) 含双硫键化合物、及其制法和药物组合物与用途
RU2802964C2 (ru) Твердые формы 2-(5-(4-(2-морфолиноэтокси)фенил)пиридин-2-ил)-n-бензилацетамида
CN109988214B (zh) 白桦脂醇晶c型物质及制备方法和其组合物与用途
JPS59231057A (ja) カルボン酸アミド化合物およびその誘導体
JPH0587069B2 (enExample)